SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Zoledronic Acid Injection, USP in ...

This long-term study, which extended the HORIZON (Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly) Pivotal Fracture Trial by three years, is a multi-center, double-blind, ...

Please provide your email address to receive an email when new articles are posted on . A single dose of zoledronic acid effectively maintains large and rapid gains in spine and hip bone mineral ...

The U.S. Food and Drug Administration (FDA) has approved Reclast® (zoledronic acid) Injection, the first and only once-yearly treatment for postmenopausal osteoporosis. Approximately 8 million women ...

Please provide your email address to receive an email when new articles are posted on . Published results showed integration of fracture liaison and orthopedic services, as well as inpatient ...

Zoledronic acid 5 mg/100 mL bottle; solution for IV infusion. Paget’s disease of bone is characterized by greatly increased and disorderly bone remodeling. Excessive osteoclastic bone resorption is ...

Initial experience of radium-223 treatment for metastatic castrate resistant prostate cancer in community setting. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract ...

BRAMPTON, Ontario--(BUSINESS WIRE)--Taro Pharmaceuticals Inc. has initiated a voluntary Type 1 recall to the patient level on six (6) lots of Taro-Zoledronic Acid Injection, 5 mg/100 mL in 100 mL ...

August 22, 2008 — Concomitant zoledronic acid (Zometa, Novartis) that is given during adjuvant endocrine therapy can prevent bone loss in premenopausal breast cancer patients. It also improves ...

Vancouver, British Columbia — A highly controlled retrospective analysis suggests that denosumab (Prolia) leads to greater reduction in fracture risk than does zoledronic acid (Reclast) among ...